NTRK1 and neoplasm: The patient we identified as having a tumor harboring an ETV6–NTRK3 fusion was a 55-year old male with T3N0M1 small intestine GIST who was treated with oral LOXO-101 (Loxo Oncology, Stamford, CT, USA), the only selective TRK inhibitor in clinical development, in a Phase I trial (NCT 02122913) [42].